In addition to managing all cardiovascular risk factors, providers must consider social determinants of health
FRIDAY, Jan. 14, 2022 (HealthDay News) — A comprehensive approach is recommended for management of cardiovascular risk factors among patients with type 2 diabetes (T2D), according to an American Heart Association scientific statement published online Jan. 10 in Circulation.
Joshua J. Joseph, M.D., M.P.H., from The Ohio State University in Columbus, and colleagues developed a scientific statement based on current evidence relating to cardiovascular health in patients with T2D.
The researchers note that management of cardiovascular risk factors remains poor in T2D, with many patients not meeting control targets for hemoglobin A1c, blood pressure, low-density lipoprotein cholesterol, and body mass index. A comprehensive approach to management of all cardiovascular risk factors is recommended for patients with T2D, including glycemia, blood pressure, lipid abnormalities, thrombotic risk, obesity, and smoking. Lifestyle and pharmaceutical interventions with proven benefit are recommended using a patient-centered approach. In addition to clinical care and treatment, social determinants of health must be considered.
“Social determinants of health, which includes health-related behaviors, socioeconomic factors, environmental factors, and structural racism, have been recognized to have a profound impact on cardiovascular disease and type 2 diabetes outcomes,” Joseph said in a statement. “People with type 2 diabetes face numerous barriers to health, including access to care and equitable care, which must be considered when developing individualized care plans with our patients.”
Several authors disclosed financial ties to the pharmaceutical and medical device industries.
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis